ResearchMoz

Term Life Assurance in the UK, Key Trends and Opportunities to 2017

Timetric
Published Date » 2014-01-09
No. Of Pages » 64
 
     
 
  Synopsis  
  
   
 
 
 The report provides market analysis, information and insights into the UK term life assurance business. 
 It provides a snapshot of market size and market segmentation. 
 It analyzes drivers and the outlook for the market. 
 It provides information on distribution channels for term life assurance products in the UK. 
 It rounds up deals, news and regulatory developments. 
 It provides a detailed analysis of the competitive landscape and key product features. 
 
 
   
  Summary  
     
 New business premiums in the term life assurance category grew by 7.7% in 2012, accompanied by an increase in mortgage-related protection sales. Term life assurance (excluding accelerated critical illness benefit) dominated the UK long-term protection...
Table of Content

1 Executive Summary

2 Introduction
2.1 What is this Report About?
2.2 Definitions
2.3 Methodology
2.4 Market Size
2.4.1 Level-term and decreasing-term assurance new business premiums
2.4.2 UK long-term protection market, new business regular premiums by category
2.4.3 Number of new term life assurance policies sold
2.5 Market Drivers
2.6 Market Outlook 
2.7 Distribution Channels

3 Competitive Landscape
3.1 Best Performers of 2012
3.2 Term Life Assurance – SWOT Analysis

4 Porter’s Five Forces Analysis
4.1 Bargaining Power of Suppliers: Low to Medium
4.2 Bargaining Power of Buyers: Medium to High
4.3 Barriers to Entry: Medium
4.4 Intensity of Rivalry: High
4.5 Threat of Substitutes: Medium

5 Deals and News
5.1 Aviva Launches Life Insurance Radio Advertising Campaign
5.2 Royal London Completes Co-Op Acquisitions
5.3 Aegon Improves Financial and Non-Medical Underwriting Limits for Protection
5.4 LV= Develops Corporate Life Product
5.5 Aviva Predicts Rise in Non-Advised Protection Sales As It Closes Direct Advice Arm
5.6 Ageas Launches Business Protection Product Suite
5.7 Ageas Adds ‘Life of Another’ Option to Product Range
5.8 Zurich and Guardian Launch Life Navigator Campaign

6 Regulation and Compliance
6.1 Regulatory Changes
6.1.1 Risk selection by gender has been outlawed
6.1.2 Retail Distribution Review
6.1.3 ‘I minus E’ taxation change
6.1.4 Consumer Insurance Act
6.1.5 Mortgage Market Review
6.1.6 Solvency II

7 Economic Backdrop
7.1 Real GDP Growth
7.2 Housing and Mortgage Market
7.1 Demographics

8 Company Profiles
8.1 Aegon UK Plc
8.1.1 Aegon UK Plc – key facts
8.1.2 Aegon UK Plc – main products 
8.1.3 Aegon UK Plc – main competitors
8.1.4 Aegon UK Plc – key employees
8.2 Aviva Plc – Company Overview 
8.2.1 Aviva Plc – key facts 
8.2.2 Aviva Plc – main products 
8.2.3 Aviva Plc – main competitors 
8.2.4 Aviva Plc – key employees 
8.3 Ageas UK Ltd – Company Overview
8.3.1 Ageas UK Ltd – key facts 
8.3.2 Ageas UK Ltd – main products 
8.3.3 Ageas UK Ltd – main competitors
8.3.4 Ageas UK Ltd – key employees
8.4 Friends Life Group Plc – Company Overview
8.4.1 Friends Life Group Plc – key facts
8.4.2 Friends Life Group Plc – main products 
8.4.3 Friends Life Group Plc – main competitors 
8.4.4 Friends Life Group Plc – key employees
8.5 Legal and General Group – Company Overview 
8.5.1 Legal and General Group – key facts
8.5.2 Legal and General Group – main products
8.5.3 Legal and General Group – main competitors
8.5.4 Legal and General Group – key employees 
8.6 Liverpool Victoria Group – Company Overview 
8.6.1 Liverpool Victoria Group – key facts 
8.6.2 Liverpool Victoria Group – main products 
8.6.3 Liverpool Victoria Group – main competitors
8.6.4 Liverpool Victoria Group – key employees 
8.7 Lloyds Banking Group – Company Overview 
8.7.1 Lloyds Banking Group – key facts 
8.7.2 Lloyds Banking Group – main products 
8.7.3 Lloyds Banking Group – main competitors 
8.7.4 Lloyds Banking Group – key employees 
8.8 Prudential Plc – Company Overview 
8.8.1 Prudential Plc – key facts 
8.8.2 Prudential Plc – main products 
8.8.3 Prudential Plc – main competitors 
8.8.4 Prudential Plc – key employees 
8.9 Royal London Group – Company Overview 
8.9.1 Royal London Group – key facts 
8.9.2 Royal London Group – main products 
8.9.3 Royal London Group – main competitors 
8.9.4 Royal London Group – key employees 
8.10 Zurich Financial Services Ltd – Company Overview 
8.10.1 Zurich Financial Services Ltd – key facts 
8.10.2 Zurich Financial Services Ltd – main products 
8.10.3 Zurich Financial Services Ltd – main competitors 
8.10.4 Zurich Financial Services Ltd – key employees 

9 Statistics 
9.1 Review Period 
9.2 Forecast Period 

10 Appendix 
10.1 Methodology 
10.2 Contact Timetric 
10.3 About Timetric 
10.4 Timetric’s Services 
10.5 Disclaimer

List of Tables


Table 1: Insurance Industry Definitions 
Table 2: Term Life Assurance – SWOT Analysis
Table 3: Recent and Upcoming Regulatory Changes
Table 4: Aegon UK Plc, Key Facts 
Table 5: Aegon UK Plc, Main Products
Table 6: Aegon UK Plc, Key Employees 
Table 7: Aviva Plc, Key Facts 
Table 8: Aviva Plc, Main Products 
Table 9: Aviva Plc, Key Employees 
Table 10: Ageas UK Ltd, Key Facts 
Table 11: Ageas UK Ltd, Main Products 
Table 12: Ageas UK Ltd, Key Employees 
Table 13: Friends Life Group Plc, Key Facts 
Table 14: Friends Life Group Plc, Main Products 
Table 15: Friends Life Group Plc, Key Employees 
Table 16: Legal and General Group, Key Facts 
Table 17: Legal and General Group, Main Products 
Table 18: Legal and General Group, Key Employees 
Table 19: Liverpool Victoria Group, Key Facts 
Table 20: Liverpool Victoria Group, Main Products 
Table 21: Liverpool Victoria Group, Key Employees 
Table 22: Lloyds Banking Group, Key Facts 
Table 23: Lloyds Banking Group, Main Products 
Table 24: Lloyds Banking Group, Key Employees 
Table 25: Prudential Plc, Key Facts 
Table 26: Prudential Plc, Main Products 
Table 27: Prudential Plc, Key Employees
Table 28: Royal London Group, Key Facts
Table 29: Royal London Group, Main Products
Table 30: Royal London Group, Key Employees
Table 31: Zurich Financial Services Ltd, Key Facts
Table 32: Zurich Financial Services Ltd, Main Products
Table 33: Zurich Financial Services Ltd, Key Employees 
Table 34: UK Term Life Assurance – New Business Premiums (GBP Thousand), 2008–2012 
Table 35: UK Term Life Assurance – New Business Premiums (GBP Thousand), 2013–2017

List of Figures


Figure 1: UK Term Life Assurance (Excluding Accelerated CI) – Total New Business Premiums (GBP Million), 2008–2012 
Figure 3: UK Long-Term Protection Market – New Business Regular Premiums by Category (GBP Million), 2008–2012 
Figure 4: Number of New Term Life Policies Sold by FSA-Regulated Life Insurers, Excluding Accelerated CI (Thousands), 2008–2012 
Figure 5: New Business Premiums for UK Term Life Assurance, Excluding Accelerated CI (GBP Million), 2013–2017 
Figure 6: Top 10 Term Life Assurance Providers Based on Total New Business Premium (Excluding Accelerated CI), 2012 (%) 
Figure 7: UK Term Life Assurance – Five Forces Analysis 
Figure 8: The UK’s Insurance Regulatory Framework 
Figure 9: Real GDP Growth (%), 2008–2017 
Figure 10: Simple Average House Prices in the UK (GBP), 1991–2012 
Figure 11: Number of First-Time Homebuyers (Thousands), 2002–2012 
Figure 12: Total Gross Mortgage Lending (GBP Million), 2002–2012 
Figure 13: Growing and Aging Population, 1995–2012 
Figure 14: UK Population Aged Over 65 (%), 1995–2017 
Figure 15: UK Overall Life Expectancy (Years), 1995–2017 
Figure 16: Improving Living Standards in the UK (GBP Thousand), 1997–2011 

Upcoming Reports:

Remanufactured Medical Imaging Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
According to the Food and Drug Administration, U.S., remanufacturing of medical devices is defined as the processing, conditioning, repackaging, renovating, restoring additional features/updates to finished device, which takes the scope of finished device’s performance beyond its original position i.e. better than original device. As per the European Coordination Committee of the Radiological, Electrochemical and Healthcare IT Industry (COCIR), Japan Industries Association of Radiological Systems (JIRA) AND Medical Imaging and Technology Alliance (MITA), the remanufacturing of...
Orthobiological Products Market - Global Industry Analysis, Market Size, Market Share And Forecasts, 2012 - 2018
By - Transparency Market Research
The global orthobiological products market is expected to grow to $15.3 billion by the year 2022 as a result of tremendous growth in the medical devices industry mainly due to increase in aging population. Growth of orthobiological products is driven by increasing awareness towards adoption of orthobiologics, development in technology, and increasing number of orthopedic related procedures.  As population continues to grow, there is simultaneous rise in aging population which is contributing to the growth of the orthobiological products industry as need for orthopedic...
C-Reactive Protein Testing Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
C-reactive protein (CRP) is an immunoprotein synthesized in liver, and plays an important role in the activation of the complement system. CRP is expressed in very low levels under normal conditions, but increases 1,000 fold within 24 hours of infection or tissue damage. Main causes of increased CRP levels include trauma, infection, inflammatory arthritis, and certain types of cancers. Recent research has found that the level of CRP may rise in cases of arteriosclerosis in which damaged blood vessel walls initiate an inflammatory response. This research has received great attention and now...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
New Materials Creation Strategy
Sep 1, 2014  
Scientists always aim at theorizing about new compounds and materials; however after Researchers have made use of X-ray scattering in a process known as molecular beam epitaxy (MBE) to understand atom behavior as a kind of material called as layered oxides were getting formed. For computational predictions of new materials, the available observations were utilized for providing insights on...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...
Fonterra Ties Up With Beingmate to Tap into China’s Baby Food Market
Aug 28, 2014  
Fonterra Co-Operative Group Ltd. will partner with Beingmate Group Co, China’s biggest infant formula manufacturer to increase its reach in the Chinese market. The New Zealand-based company makes this move with the intent to grab a bigger market share in China after it suffered many setbacks in the food-safety scandal last year.   This partnership will also help Beingmate...
Chinas Leading Asset-Management Company Aims for IPO
Aug 28, 2014  
China’s biggest asset-management company plans to go public by the end of 2015. Chinese authorities are constantly ramping up their interests towards introducing mixed ownership to state-owned huge companies and call for more private capital investments into the economy. According to the news report, China Huarong Asset Management Co., Ltd. will collaborate with eight investors...